Biogen (NASDAQ:BIIB) Price Target Cut to $265.00 by Analysts at Canaccord Genuity Group
Biogen (NASDAQ:BIIB – Get Free Report) had its target price lowered by equities researchers at Canaccord Genuity Group from $298.00 to $265.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective indicates a potential upside of 92.97% from the stock’s […]
Biogen (NASDAQ:BIIB – Get Free Report) had its target price lowered by equities researchers at Canaccord Genuity Group from $298.00 to $265.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective indicates a potential upside of 92.97% from the stock’s […]
